Traditional Chinese medicine added to standard care for moyamoya disease
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether a traditional Chinese herbal formula (Fufang Tongluo Decoction) can improve outcomes when added to aspirin and atorvastatin for people with moyamoya disease, a condition that narrows brain arteries and increases stroke risk. The study aims to see if this combination reduces stroke risk and improves overall well-being.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have been diagnosed with moyamoya disease, confirmed by imaging tests like MRI or angiography.
- Your condition fits a Traditional Chinese Medicine pattern called 'phlegm-stasis obstructing the collaterals' (your doctor will confirm this).
- You have been on stable treatment for at least one month, such as blood thinners or blood pressure medication, and your health conditions are well controlled.
- You can follow the trial's rules and give your consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a Chinese herbal formula called Qiqi Shengmai can help people with moyamoya disease, a condition that narrows blood vessels in the brain. It aims to see if the herbal treatment is safe and might improve symptoms.
This study tests whether daily aspirin, a special physical therapy called remote ischemic conditioning (RIC), or both can slow down moyamoya disease, a condition that narrows brain blood vessels and increases stroke risk. Participating may help you manage your condition and possibly prevent it from getting worse.
This study tests if statins (cholesterol-lowering drugs) can help people with Moyamoya disease. The trial will follow patients who receive either surgery or standard care to see if adding a statin improves outcomes.
This trial follows people with moyamoya disease who are treated with medication only, and it also looks at first-degree relatives. The goal is to understand long-term outcomes and whether careful conservative care is beneficial over time.
This study at Vanderbilt tests whether certain biomarkers (signs in your blood or brain scans) can help tailor care for people with Moyamoya, a condition where blood flow to the brain is reduced. Participants will have brain scans and complete study procedures before and after surgery to improve blood flow.
This study looks at how Moyamoya disease changes over time and what predicts outcomes. It uses approved brain imaging and, likely, thinking/memory tests to understand prognosis.
Hear when a new Moyomoya Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.